MarketLine Blog

Posts tagged to Roche

AstraZeneca agrees $6.9bn deal with Daiichi Sankyo: UK drug maker could dominate the future breast cancer therapy market

MarketLine

The joint development and commercialization of a new breast cancer therapy indicated for the treatment of HER-2 positive breast cancer has the potential to help the AstraZeneca in its quest for a larger oncology market share. If approved, it will join Lynparza (olaparib) – a PARP inhibitor marketed by AstraZeneca for the treatment of HER negative breast cancer. The addition of a new breast cancer therapy to the AstraZeneca product portfolio will almost certainly increase the company’s market share. Roche currently dominates the treatment of HER-2 positive breast cancer with… Read more